English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 2 August 2023, 21:38 HKT/SGT
Share:
Kingworld Medicines Expects 1H Profit Increased By 35%-40%
Demonstrating Strong Business Performance and Competitive Strengths

HONG KONG, Aug 2, 2023 - (ACN Newswire) - Kingworld Medicines Group ("Kingworld Medicines" or the "Group", stock code: 01110.HK), a leading healthcare distribution company, announced a projected rise in profit for the first half of the fiscal year. Based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ending June 30, 2023, the Group anticipates a profit surge ranging from approximately 35% to 40% for the period, compared to the same period last year.

The Board attributes this profit increase to increased revenue and gross profit stemming from the distribution of imported branded pharmaceutical and healthcare products in China, with growth rates reaching approximately 30% to 35% and 15% to 20%, respectively. Additionally, the Group's share of profit from a joint venture saw a boost of approximately 55% to 60% compared to the same period last year. This surge is attributed to the market recovery after the COVID-19 pandemic control measures.

Kingworld Medicines is a company specializing in the distribution of imported branded pharmaceutical and healthcare products in China. The Group adeptly navigated post-pandemic market changes, propelling business expansion by leveraging its industry strengths.

Mr. Zhao Lisheng, Chairman of the Board of Kingworld Medicines Group, commented: "The Group's profit increase was mainly due to market recovery and the Group's employees' unremitting efforts, which adapted post-pandemic. The Group's strengths lie in its strong capabilities in distributing pharmaceutical and healthcare products and its acute insights into the market. Besides, the Group has achieved long-term steady growth by continuously improving efficiency and expanding its business."

Looking ahead, Kingworld Medicines Group will continue to focus on increasing market share, expanding business coverage, and improving efficiency to further enhance the company's profitability and market competitiveness.


Topic: Press release summary Sectors: Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
playX Secures Industry-Leading Player Protection Through Landmark Insurance Partnership with Great American Insurance Group  
Feb 8, 2026 23:30 HKT/SGT
Mr Liu Xiaojun, on behalf of Fufeng Group, has fully completed the acquisition of Viva World Trade, Inc.  
Feb 7, 2026 05:45 HKT/SGT
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets  
Feb 6, 2026 17:45 HKT/SGT
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share  
Feb 6, 2026 17:01 HKT/SGT
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization  
Feb 6, 2026 16:34 HKT/SGT
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis  
Feb 6, 2026 14:17 HKT/SGT
Spritzer Celebrates Continued Excellence with Dual Recognition at Putra Brand Awards 2025 and Superior Taste Award 2025  
Feb 6, 2026 13:13 HKT/SGT
Mitsubishi Motors Launches the All-New Versa Van in the Philippine Market  
Friday, February 6, 2026 12:34:00 PM
Eternal Beauty Holdings Limited and Lane Crawford Debut Landmark Fragrance, Further Expanding Footprint in High-Margin Niche Fragrance Market  
Feb 6, 2026 12:21 HKT/SGT
Distinct Healthcare Successfully Listed on HKEX, Bolstered by Premium Customer Base and All-Star Cornerstone Investors  
Feb 6, 2026 11:44 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575